Two-Drug combo shows promise against Hard-to-Treat leukemia
NCT ID NCT02756897
First seen Mar 05, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests whether combining two targeted drugs, venetoclax and ibrutinib, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It includes 234 patients whose cancer has returned or is hard to treat, as well as some untreated high-risk patients. The goal is to see how many patients achieve a complete response, while monitoring side effects like low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.